Across TCGA pan-cancer cohorts, AMZ2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AMZ2 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AMZ2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMZ2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where AMZ2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.557	0.886	.003	16	view →
UCEC	OS	Median	All	1.000	0.844	.003	8	view →
LSCC	DFS	Median	III,IV	0.490	0.855	.041	7	view →
LUAD	OS	Quartile	III,IV	0.578	1.000	.024	5	view →
HNSC	OS	Tertile	IV	0.594	1.000	.014	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AMZ2 tumor-vs-normal RNA expression · all AMZ2 data types